9 years ago

Enterprise Therapeutics Raises £4 Million for Respiratory Disease Therapies

  • Enterprise Therapeutics, a UK-based drug discovery company, has secured £4 million in funding led by Epidarex Capital and Imperial Innovations

  • The company intends to use the funds to accelerate its three drug discovery projects towards drug candidate selection

  • Enterprise Therapeutics focuses on developing muco-regulatory therapies for patients with respiratory diseases such as cystic fibrosis, COPD, and severe asthma.

      • ProblemHealthcare

      "Patients suffering from respiratory diseases like cystic fibrosis, chronic obstructive pulmonary disease, and severe asthma struggle with excessive mucus buildup in their airways, leading to breathing difficulties, infections, and other complications."

      Solution

      "Enterprise Therapeutics is developing innovative therapies that target the mechanisms involved in mucus production and clearance in the lungs. Their goal is to help patients breathe easier by reducing mucus buildup and improving lung function."

      Covered on